Obesity

• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

Tables and Figures - Obesity

• Page 4: Classification of Overweigh and Obesity by BMI
• Page 4: Waist Circumference - High Risk
• Page 5: Classification of Overweight and Obesity by BMI, Waist Circumference and Associated Disease Risk
• Page 6: NHANES Estimates of Obese Population (%), Percent of Population of Obese in each age group (BMI ≥ 30), Risk Factors Associated with Increased Morbidity and Mortality in Obese Persons
• Page 8: AVOS Population Projection by Year
• Page 9: Obesity Patient Population Model
• Page 17: U.S. Obesity Market Model, 2004-2013
• Page 18: U.S. Obesity Market Model, 2004-2013, continued
• Page 19: Treatment Algorithm
• Page 20: Treatment Decision Tree
• Page 22: Anti-Obesity Product Differentiation
• Page 23: Physician Product Ratings
• Page 24: AVOS Physician Panel Market Trend Forecasts
• Page 27: Marketed Products in the United States
• Page 28: Timeline of Major Market Events
• Page 31: Xenical Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 32: Decline in Xenical RRx, NRx and TRx
• Page 34: Meridia Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 37: Phentermine Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 39: Phendimetrazine, Diethylproprion and Benzphetamine Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 41: Cetilistat Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 43: Rimonabant Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 46: Taranabant; CP-945, 598; and SLV-319 Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 50: Lorcaserin Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 53: Liraglutide Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 55: Pramlintide + Leptin Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 57: Clinical Success Rates of Anti-obesity Agents: 1990-Present
• Page 59: Drugs in Development